Guardant Health grows with Shield blood CRC screening, Quest deal, 50M reach, 335% surge, and FY25 revenue $981M up 33%. Read ...

On Tuesday, the Centers for Medicare & Medicaid Services (CMS) approved the Advanced Diagnostic Laboratory Test (ADLT) status for Guardant Health, Inc.’s (NASDAQ:GH) Shield blood test for colorectal ...

Guardant Health, Inc., a leading precision oncology company, today announced its Shield blood test for colorectal cancer screening is now covered for active-duty service members and their families ...

The Guardant Health Shield test, one committee member said, “is better than nothing for patients who are getting nothing, but it is not better than a colonoscopy.” By Gina Kolata A committee of ...

PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (GH), a leading precision oncology company, today announced its Shield blood test for colorectal cancer (CRC) screening has been named a ...

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the National Cancer Institute (NCI) has selected the company’s Shield™ ...

Guardant Health has reported an encouraging clinical readout update on the performance of its latest algorithm for the Shield blood test for colorectal cancer (CRC) screening. The latest screening ...